So many 5-ASA trials, so many guidelines - but what is the best dose and route we should be prescribing? According to Dr. Brigida Barberio and colleagues, network meta-analysis supports many aspects of current international guidelines, but highlights a key role for higher doses of oral 5-ASA for induction of remission in more extensive disease.

Dr. Neeraj Narula reports a post-hoc analysis of the UNITI Crohn’s trials showing that early measurement of faecal calprotectin after induction therapy predicts clinical outcomes better than baseline measurements of calprotectin and than other week 6 clinical or biomarker data.

Alison de Lima and Janneke van der Woude discuss their article summarising the available evidence on the management of pregnancy in IBD in the context of the COVID-19 pandemic.

Tofacitinib treats ulcerative colitis, but how? Dr Kristina Lechner describe an elegant series of experiments elucidating the effects of tofacitinib on T cell function in colitis with some surprising findings on cellular trafficking.

Mads Wewer reports on the analysis of population data from Denmark tracking the incidence and complications of peri-anal Crohn’s disease.

Dr Christopher Cardinale describes his work to uncover the effects of a non-coding SNP on signalling through the JAK2 pathway.

Dr John Nik Ding reports his study of urine, faecal and serum metabonomic and microbial predictors of response to anti-TNF therapy in 76 Crohn’s patients.

Nathalie Auger and Marianne Bilodeau-Bertrand describe their absolutely enormous epidemiological study of 3 decades of data from Quebec, Canada identifying birth-defects for offspring of almost 22,000 mothers with IBD.

Sabita Roy reports his work linking prescription opioids with increased gut dysbiosis, alterations in epithelial tight junction function and colitis severity in 2 different murine models of colitis.

Fascinating results from Nadia Pillai, using real world data from a Swiss IBD cohort to model the cost-effectiveness of early biologic therapy. Early use of biologics is not cost effective in this cohort, but this outcome changes with biologic price drops or with more careful patient selection.